PBA
ASMB icon

Paradigm Biocapital Advisors’s Assembly Biosciences ASMB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7M Buy
1,553,748
+888,497
+134% +$24.2M 0.8% 20
2026
Q1 		$18.5M Hold
665,251
– – 0.38% 33
2025
Q4 		$22.6M Buy
+665,251
New +$21.4M 0.58% 27

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Paradigm Biocapital Advisors's ASMB Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Assembly Biosciences (ASMB) stake by 134% in Q2 2026, buying an estimated $24.2M and bringing the position to 1,553,748 shares worth $42.7M. The position accounts for 0.8% of the portfolio, ranked #20.

Paradigm Biocapital Advisors first reported a position in ASMB in Q4 2025 and has held it in 3 quarters since. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Paradigm Biocapital Advisors held 1,553,748 shares of Assembly Biosciences worth $42.7M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 888,497 Assembly Biosciences shares in Q2 2026, an estimated $24.2M.
  • Assembly Biosciences made up 0.8% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #20 holding.
  • Paradigm Biocapital Advisors first reported a position in Assembly Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.